In an article in The Nation about ACT UP’s legacy of further deregulating the US Food and Drug Administration (FDA), Yale School of Public Health’s Gregg Gonsalves cited NBCC’s work on why FDA reform, not lack of regulation, is important for patients’ rights:
“Drugs must be approved based on clinically meaningful outcomes rather than unvalidated surrogate endpoints… we need more drugs that save or meaningfully improve patients’ lives, not simply more drugs.”
Learn more about NBCC’s position on FDA reform.
